Inhibition of platelet aggregation using anti-human GPVI antibodies
US11692033B2 · kind B2 · utility
0Cited by
11References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 2, 2018 |
| Grant date | Jul 4, 2023 |
| Priority date | — |
| Expiry date | May 2, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.